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A novel mass spectrometry-based assay system for determining protein kinase activity
employing mass-tagged substrate peptide probes was used for the diagnosis of tumors. Two
peptide probes (H-type and D-type) were synthesized containing the same substrate peptide
sequence for protein kinase C (PKC). The molecular weights of the two probes differ because
of the incorporation of deuterium into the acetyl groups of the D-type probe. The lysates of the
normal and tumor tissue were prepared and reacted with the H- and D-type peptide probes,
respectively. The PKC activities of the normal and tumor tissues can be compared simply and
directly by calculating the phosphorylated ratio to each peptide probe, obtained from the peak
intensity of the mass spectrum after mixing of the two reaction solutions. The phosphorylation
ratio for the reaction of the H-type peptide probe with the tumor tissue lysate (B16 melanoma)
was more than three times higher than that of the D type peptide probe with the normal skin
tissue lysate. These results show that the novel assay system for detecting protein kinase
activity using mass-tag technology can be a simple and useful means to profile protein kinase
activity for cell or tissue lysate samples, and can be applied to the diagnosis of tumors. (J Am
Soc Mass Spectrom 2007, 18, 106–112) © 2007 American Society for Mass SpectrometryLiving cells contain numerous signal transductionpathways that respond to extracellular signals toregulate or modulate the respective gene expres-
sions. Extracellular signals either penetrate the cellular
membrane or bind to the extracellular domain of the
receptors. These activated receptors are able to change
the amount or intracellular distribution of second mes-
sengers through the use of effectors. The second mes-
sengers also activate the protein targets that control the
final gene expression by acting on targets further down-
stream. In these intracellular signal transduction path-
ways, phosphorylation by protein kinases is one of the
most versatile processes in cellular growth and function
through activation of the target proteins [1, 2].
Protein kinase C (PKC), a phospholipid-dependent
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doi:10.1016/j.jasms.2006.09.004serine/threonine kinase, appears to be involved in the
signal transduction response to a variety of hormones
and growth factors. The phosphorylation of serine or
threonine residues by PKC has an important influence
on diverse biological phenomena such as signal trans-
duction, cell division and motility, apoptosis and carci-
nogenesis [3, 4].
PKC isozymes are classified into three subfamilies
based on structural and activational characteristics:
conventional or classic PKCs (cPKCs; , , and ), novel
or nonclassic PKCs (nPKCs; , , , and ), and atypical
PKCs (, 	, and 
) [3, 4]. The activation of cPKCs
requires diacylglycerol (DAG) as an activator and phos-
phatidylserine (PS) and Ca2 as activation cofactors.
The nPKCs are regulated by DAG and PS, but do not
require Ca2 for activation. In the case of atypical PKCs,
their activity is stimulated only by PS, and not by DAG
and Ca2 [3, 4].
In many diseases, extraordinary activation of certain
protein kinases has been reported. For example, over-
expression or hyperactivation of PKC has been re-
ported in several cancer cells or tissues (e.g., melanoma,
breast cancer, and hepatoma) as having increased [3–7].
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important issue in the diagnosis and treatment of dis-
eases or in drug development.
The most common protein kinase activity assay is the
radioactive assay based on the use of [32P]ATP in the
phosphorylation of specific peptides or proteins. How-
ever, this method presents some disadvantages, such as
the short half-life of 32P isotope, the generation of
hazardous ionizing radiation, and the difficulty in iso-
lating the phosphorylated substrates [8]. For these rea-
sons, a number of nonradioactive assays such as bio-
sensors [8], fluorometric assay [9, 10] and ELISA [11, 12]
were developed recently for measuring protein kinase
activities. We previously reported a novel assay system
(defined as mass-tag technology) for determining pro-
tein kinase activity, using mass-tagged substrate pep-
tide probes and mass spectrometry. This method is a
simple and sensitive method to profile the protein
kinase activity [13].
In the present study, the mass-tag technology re-
sponding to intracellular signals, especially PKC, was
developed as a novel assay system for the diagnosis of
tumors. This study showed that the mass-tag technol-
Figure 1. H-type and D-type peptide probe.
Figure 2. Ionization efficiency of the phosph
peptides, AAFKKQGSFAKKK and its phosphory
ing a phosphorylated Ser at the phosphorylation
mixed in a ratio of 1:1 (vol/vol) at concentration
and then identified by MALDI-TOF mass spectrometogy is a simple and useful method to profile the protein
kinase activity in vivo and could be applied for the
diagnosis of tumor.
Experimental
Synthesis of Mass-Tag Probe
Peptide probes containing the originally-designed sub-
strate sequence of PKC (FKKQGSFAKKK), bearing a
Lys and two Ala residues at the N-terminus, were
synthesized using an automatic peptide synthesizer
according to standard Fmoc-chemistry: two Ala gave no
effect on the phosphorylation of peptide probes. Two
normal acetyl groups (CH3CO-) or deuterated acetyl
groups (CD3CO) were incorporated into the Lys residue
at the N-terminus (Figure 1). After treatment with TFA,
the peptide was purified on an Inertsil ODS-3 column
(250  20 mm, 3.5 m, GL Sciences Inc., Tokyo, Japan)
using a BioCAD Perfusion Chromatography system
(Ikemoto Scientific Technology Co., Tokyo, Japan) un-
der a linear A-B gradient, at a flow-rate of 8 ml/min,
where eluent A was 0.1% TFA in water and eluent B
was 0.1% TFA in acetonitrile.
Lysate Preparation from Tissues
In the present study, all animal studies were performed
in accordance with the Guidelines for Animal Experi-
ments of the Kyushu University.
B16 melanoma cells were maintained in Dulbecco’s
modified Eagle’s medium (DMEM) (Gibco Invitrogen
ted and the unphosphorylated peptide. Two
peptide (AAFKKQGphosphoSFAKKK) contain-
, were synthesized. Two peptide solutions were
0, 60, 120, and 300 M, combined with CHCA,oryla
lated
site
s of 3ry.
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bovine serum, penicillin (100 U/ml), streptomycin (100
g/ml), and amphotericin B (0.25 g/ml). The cells
were kept in a humidified atmosphere containing 5%
CO2 and 95% air at 37 °C.
Male 5-week old Kud:ddY mice, weighting 25 g,
were used in this study. The dorsal side was shaved and
was inoculated subcutaneously with 1  106 cells per
100 l of Hanks’ balanced salt solution (Gibco) per
animal. Tumors were allowed to grow to a mean
diameter of 0.7 to 1.0 cm.
Mice were sacrificed and the tumors were excised.
After the tumors were weighed, they were homoge-
nized in 10 ml of buffer [20 mM Tris-HCl, pH 7.5, 250
mM sucrose, and protease inhibitor-EDTA free (Roche,
Tokyo, Japan)]. The homogenate was centrifuged at
1000  g at 4 °C for 10 min and the supernatant was
removed. After washing with 5 ml of buffer and recen-
trifuging, 1 ml of buffer was added into the precipitate
and then sonicated. After sonication, the samples were
centrifuged at 5000  g at 4 °C for 15 min, and the
resulting supernatant was used as whole lysate sample
for the phosphorylation reactions. The lysate of normal
Figure 3. Schematic illustration of the detectio
of tumors.skin tissue was also prepared by the same method.Phosphorylation Reaction for Each Peptide Probe
The Phosphorylation reaction for each peptide probe
was carried out in 50 l of buffer (20 mM Tris-HCl, pH
7.5, 10 mM MgCl2, 0.5 mM CaCl2, 200 M ATP, 2.0
g/ml DAG, and 2.5 g/ml PS) containing 30 M
peptide probe and tissue lysate at a 200 g/ml protein
concentration. After the phosphorylation reaction for
120 min at 37 °C, two solutions for the D-type and
H-type peptides were combined and identified by
matrix-assisted laser desorption/ionization-time-of-
flight (MALDI-TOF) mass spectrometry using a Voy-
ager DE RP Biospectrometry Workstation (Applied
Biosystems, Framingham, MA) in positive ion reflec-
tron mode. The -cyano-4-hydroxycinnamic acid
(CHCA) matrix (10 mg/ml) was prepared in 50% wa-
ter/acetonitrile and 0.1% TFA. The matrix and sample
were mixed in a ratio of 1:1 (vol/vol). A total volume (1
l) of the mixture was applied on the sample plate and
allowed to dry to induce crystallization, and then
analyzed by MALDI-TOF mass spectrometry. The ac-
celerating voltage was 20 kV with a 100 ns extraction
delay time. Typically, 100 laser shots were averaged to
nciple of mass-tag technology for the diagnosisn priimprove the signal-to-noise ratio. All spectra were an-
109J Am Soc Mass Spectrom 2007, 18, 106–112 MASS-TAG TECHNOLOGY FOR THE DIAGNOSIS OF TUMORalyzed using Data Explore software (Applied Biosys-
tems). The phosphorylation ratio for each peptide probe
was calculated by the formula, [phosphorylated peptide
probe/(phosphorylated peptide probe  unphosphor-
ylated peptide probe)  100].
Moreover, for the accurate estimation of phosphory-
lation ratio, we synthesized two peptides, AAFKKQGS-
FAKKK and its phosphorylated peptide (AAFKKQG-
phosphoSFAKKK) containing the phosphorylated Ser at
the phosphorylation site. Two peptide solutions were
mixed in a ratio of 1:1 (vol/vol) at concentrations of 30,
60, 120, and 300 M, combined with CHCA, and then
analyzed by MALDI-TOF mass spectrometry. As
Figure 4. Changes of phosphorylation rate f
Ro-31-7549. PKC inhibitor was added into eac
concentrations of 0, 50, 500, or 5000 nM. After 6
samples were centrifuged at 5000  g at 4 °C f
samples for the phosphorylation reaction.
Figure 5. Coupled enzyme assay of each peptide probe to
identify a difference in the phosphorylation rate between the two
peptide probes (H-type and D-type). After the phosphorylation
reaction of the two peptide probes (H-type and D-type) with
PKC, the concentration of NADH was monitored spectrophoto-
metrically at 340 nm.shown in Figure 2, the intensity in phosphorylated
peptide was 1.2 times as low as it in nonphosphorylated
peptide in all concentrations. From these results, the
phosphorylation ratio was corrected by 1.2.
Coupled Enzyme Assay
The coupled enzyme assay was performed according to
a method previously described with minor modifica-
tions [12]. Exactly 100 M the peptide probe was
incubated in 500 l of 20 mM Tris-HCl buffer solution
(pH 7.5) containing 1 mM phosphoenolpyruvate, 0.3
mM NADH, 12 U/ml lactate dehydrogenase (LDH), 4
U/ml pyruvate kinase, 10 mM MgCl2, 0.5 mM CaCl2,
200 M ATP, 2.0 g/ml DAG, 2.5 g/ml PS, and 1 ng/
ml PKC. The reaction was initiated by the addition of
ATP to buffer and was performed for 60 min at 37 °C.
The diminution of NADH was detected with an UV/
VIS spectrophotometer (model V-560, JASCO Interna-
tional Co., Tokyo, Japan), equipped with an ETC-505T
temperature controller (JASCO) at 340 nm.
Inhibition of PKC by the Addition of PKC
Inhibitor (Ro-31-7549) to B16 Melanoma Cells
1  106 cells were seeded into wells and incubated in
a humidified atmosphere containing 5% CO2 and 95%
air at 37 °C. After 24 h, PKC inhibitor (Ro-31-7549)
was added into each well at concentrations of 0, 50,
500, or 5000 nM. After 6 h from the addition of PKC
inhibitor, cells were scraped and lysed in buffer [20
mM Tris-HCl, pH 7.5, 250 mM sucrose, and protease
inhibitor-EDTA free] by sonication. The samples were
centrifuged at 5000  g at 4 °C for 15 min and the
supernatant was used as lysate samples for the phos-
obe peptides after adding the PKC inhibitor
ll containing 1  106 B16 melanoma cells at
ells were scraped and lysed by sonication. The
min, and the supernatant was used as lysateor pr
h we
h, c
or 15phorylation reaction.
tide
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Detection Principle of Mass-Tag Technology
The detection principle of mass-tag technology is
presented in Figure 3. Two types of peptide probes
(H-type and D-type) containing the same substrate
peptide sequence for the target protein kinase show
different molecular weights because of the hydroge-
nated (H-type) and deuterated (D-type) acetyl groups
at the amino-terminus. The lysate of normal skin or
melanoma tissue was prepared and reacted with the
H-type or D-type peptide probes, respectively. If each
peptide probe is phosphorylated by the target protein
kinase, the m/z values of these probes increase by 80
Da in the mass spectrum. Therefore, protein kinase
activities between normal and tumor tissue can be
compared simply and directly by calculating the
phosphorylated ratio to each peptide probe obtained
from the peak intensity in the mass spectrum after
mixing of two reaction solutions. Mass spectrometry
Figure 6. Phosphorylation reaction of each pep
H-type and D-type peptide probes were phosph
for 60 min, respectively, and the mixture of the H
spectrometry. H(p), phosphorylated H-type pephas become the core instrumental technology in re-cent postgenomic research because of its high sensi-
tivity and accuracy [14 –16]. However, mass spectros-
copy is generally disadvantaged by the poor
reproducibility among independent measurements.
Thus, stable isotope labeling is a promising way of
overcoming this problem.
Phosphorylation of Substrate Peptide by Six PKC
Isozymes (, , , , , and )
PKC, , , , , and  are mostly detected in the normal
skin and/or B16 melanoma tissues [6, 17]. Among these
isozymes, hyperactivation of PKC in tumor cells includ-
ing melanoma cells has been reported. We designed an
original peptide sequence for PKC phosphorylation for
use as mass-tagged probes. Then, two peptide probes
(H-type and D-type) were phosphorylated by these six
PKC isozymes. The two peptide probes showed a higher
phosphorylation rate on PKC (61–65%) than other PKC
probes in the absence or presence of PKC. The
ted in the presence or absence of PKC at 37 °C
e and D-type samples was detected using mass
probe.tide
oryla
-typisozymes (, , , , and ) (20%) after 60 min reaction in
type
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0.1 g/ml enzyme concentration.
Moreover, the addition of Ro-31-7549 (a selective inhib-
itor of PKC) into B16melanoma cells leads to a decrease in
the phosphorylation rate for the probes. At a concentra-
tion of 5000 nM, a decrease of over 80% was identified
compared with no addition (Figure 4). The Ro-31-7549
selectively inhibits PKC, especially cPKCs, by competing
with ATP for the cosubstrate site. PKC is inhibited by
Figure 7. Phosphorylation reaction of each
melanoma tissue lysate (filled circle). The H-t
melanoma tissue lysate and with normal skin tis
mixture of H-type and D-type samples was d
spectra of unphosphorylated peptide probes and
change of the phosphorylation rate of two ph
H-type peptide probe; D(p), phosphorylated D-Ro-31-7549 with an IC50 value of 50 nM, but IC50 values ofPKC  or  is 160 nM [18, 19]. These results show that
the peptide probes used in this study may have specificity
for PKC.
Coupled Enzyme Assay of Each Peptide Probe
To confirm whether there is a difference in phosphoryla-
tion rate between the two peptide probes (H-type and
D-type), the time courses of the phosphorylation in both
de probe with normal skin (open circle) or
nd D-type peptide probes were reacted with
ysate at 37 °C for 120 min, respectively, and the
d using mass spectrometry. (a) Typical mass
phorylated peptide probes. (b) Time-dependant
orylated peptide probe. H(p), phosphorylated
peptide probe.pepti
ype a
sue l
etecte
phos
osphprobes were identified by a coupled enzyme assay. When
112 KANG ET AL. J Am Soc Mass Spectrom 2007, 18, 106–112the peptide probe is phosphorylated by PKC, ADP is
produced from ATP. This ADP production is coupled
with the pyruvate kinase and lactate dehydrogenase reac-
tions for oxidizing NADH. Thus, the phosphorylation time
course of the peptide probes by PKC can be monitored by
the decreasing absorbance at 340 nm for NADH.
The concentration of NADH was decreased in each
peptide probe over time. In the present study, a difference
in the phosphorylation rate between the two peptide
probes was not found, meaning that they have the same
phosphorylation sensitivity on PKC (Figure 5).
Detection of the Phosphorylation Reaction of the
Peptide Probe in the Presence of Isolated PKC
The H-type peptide probe was phosphorylated in the
presence of PKC for 60 min. On the other hand, the
D-type peptide probe was incubated in the absence of
PKC at 37 °C for 60 min. The peak of the H-type
peptide probe decreased gradually, while its phosphor-
ylated peak increased. However, no change in the peak
intensity from the D-type peptide probe was identified
over the 60 min period (Figure 6).
Phosphorylation Reaction of Each Peptide Probe
with Normal Skin or Melanoma Tissue Lysate
The H-type and D-type peptide probe were reacted
with melanoma tissue lysate and with normal skin
tissue lysate, respectively. The phosphorylation results
for each peptide probe are presented in Figure 7. The
peak of the H-type peptide probe decreased, but its
phosphorylated peptide peak increased with the lapse
of time. The phosphorylation rate for the H-type at 60
and 120 min was more than three times higher than that
for the D-type, meaning that the PKC activity in mela-
noma tissue is higher that in normal skin tissue.
It is known that the activity of PKC, especially PKC,
is higher in melanoma cells or tissues than in normal
skin cells or tissues. Moreover, there are many reports
that the activator and cofactor (DAG, PS and Ca2)
concentrations and translations of PKC from cytosol to
membrane increased in melanoma cells or tissues [3–7,
20]. Similarly, in the present study, the PKC activity in
melanoma tissue was significantly higher compared
with that in normal skin tissue.
Mass-tag technology is broadly used to identify
peptide and protein sequences responding to enzymes,
drugs, or chemicals [21, 22]. In the study, mass-tag
technology was applied for the diagnosis of tumor. Our
study shows that the novel assay system of protein
kinase activity using mass-tagged substrate peptide
probes and mass spectrometry can be applied to thediagnosis of tumor. Moreover, our mass-tag technology
is a simple and useful means to profile protein kinase
activity for cell or tissue samples.
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